January 2026 Research Update

This month, studies looking beyond standard anti-seizure medicines focused on two different goals: reducing seizures with a device, and improving daily life skills with parent-led coaching. Across these studies, seizure outcomes after vagus nerve stimulation (VNS) looked encouraging in routine care, while an online rehabilitation approach showed early signals that families may be able to make practical daily activities easier. These results sit at different stages of evidence, but together they show research moving in parallel on seizure control and everyday functioning. [1] [2] [3]

For VNS, one Dravet syndrome cohort reported that most participants reached at least a 50% seizure reduction by 12 months, and many maintained this level over long follow-up, with only minor side effects reported. [1] Another pediatric epilepsy cohort that included an SCN1A-Dravet subgroup reported responder rates that were similar between the SCN1A-Dravet subgroup and other monogenic epilepsies, and it also reported fewer episodes of status epilepticus after VNS. [2]

In a separate small feasibility study, parents of children and teens with Dravet syndrome joined eight online CO-OP sessions (a structured coaching approach that builds problem-solving around real-life goals). Parents reported significant improvements in both performance and satisfaction for the goals they practiced, and also for goals they did not directly practice, suggesting possible carryover into other activities. The study was small and had no comparison group, so it is best read as an early signal that this type of family-centered telerehabilitation is worth studying further. [3]

For families, these studies add to the picture that Dravet syndrome research is not only about finding new drugs. VNS results came from retrospective real-world follow-up, so they describe what happened in treated patients rather than proving what would happen for any one person, but they do provide longer-term context for seizure outcomes and tolerability. [1] [2]

The telerehabilitation CO-OP study is earlier-stage evidence, but it highlights something many families care about: whether supports can improve daily activities, not just seizure counts. What remains uncertain is how well these improvements hold over longer time periods, and whether similar benefits would be seen in a larger group or with a comparison group. For now, the main value is that it expands what researchers are testing as meaningful outcomes in Dravet syndrome. [3]

This month added practical information about how seizure medicines may work differently across highly treatment-resistant epilepsy and specific genetic forms that can cause Dravet syndrome. The overall pattern was mixed response: some children improved substantially with cannabidiol, many improved only a little, and a minority worsened, while a very small Dravet genetic subtype series suggested certain commonly used medicines appeared more helpful than others in that subgroup. Together, these studies reinforce that medication response in Dravet syndrome and related conditions can vary widely, and genetics may be one reason for that variability. [4] [5]

In a Canadian real-world chart review of 61 children with highly refractory epilepsy treated with highly purified cannabidiol (CBD), 22% reached at least a 50% seizure reduction, including 7% who became seizure-free, while nearly half had 25% or less reduction. Adverse effects were reported in 30%, and 6.5% stopped CBD due to side effects, but 70% stayed on treatment, often citing benefits beyond seizure control such as better behavior and sleep. Because this cohort included highly refractory epilepsy broadly (not only Dravet syndrome), it describes what happened in a difficult-to-treat population rather than providing Dravet-specific results. [4]

A separate case series focused on five people with Dravet syndrome due to 2q24.3 microdeletions, and qualitatively described how different treatments worked for them. In this small group, valproic acid, clobazam, and cannabidiol were reported as beneficial, while levetiracetam and phenobarbital were not. With only five individuals and without standardized outcome measures, the main contribution is a signal that this rarer genetic form of Dravet syndrome may have recognizable response patterns that should be tested in larger groups. [5]

For patients and caregivers, this set of studies adds context rather than a clear yes-or-no answer about any one medicine. The CBD study provides real-world expectations in a difficult-to-treat pediatric population: some children improved a lot, many improved a little, and side effects were not rare, while some families continued for reasons beyond seizure counts. [4]

The 2q24.3 microdeletion case series is mainly useful as early, subtype-specific information that might help researchers understand why a medicine seems helpful in one genetic form and not another. What remains uncertain is whether the same pattern would appear in a larger group or with more formal outcome tracking. For now, it mainly supports the idea that genetic cause can matter when studying treatment response in Dravet syndrome. [5]

This month, studies of underlying causes focused on why Dravet syndrome and Dravet-like conditions can look similar but behave differently. A large genetics dataset showed that most patients had SCN1A variants, but a small fraction had changes in other genes, and some of these genes appeared linked to different seizure patterns or different medication effects. Separately, brain imaging in SCN-related epilepsies and laboratory work in mouse models added clues about brain changes that may relate to symptoms, but these findings are not yet used to predict an individual child's course. [6] [7] [8]

In a retrospective cohort of 1,215 Chinese patients with Dravet syndrome or a Dravet-like phenotype, SCN1A variants were found in 87.3%. Among Dravet-like cases, variants were also found in genes such as PCDH19 and several GABA receptor genes, and these genetic differences were linked to clinically meaningful patterns, including clustered seizures with PCDH19 and better medication response for some GABA receptor gene variants. The study also reported that oxcarbazepine worsened seizures in patients with certain GABA receptor gene variants, while a SCN2A gain-of-function case responded favorably to oxcarbazepine, showing that the same medicine can have very different effects depending on the gene involved. [6]

A separate MRI study across SCN1A, SCN2A, SCN3A, and SCN8A-related epilepsy found that MRI abnormalities were not rare, appearing in 37.4% of 139 children, with atrophy reported most often. Abnormalities were more frequent in the SCN2A group than the SCN1A group, suggesting that MRI patterns may differ by gene, even among related sodium-channel epilepsies. Because MRI timing and protocols were not standardized, these results are best viewed as a description of patterns seen in care, not a definitive guide to what any one scan means. [7]

In laboratory research, a Dravet mouse model study found age- and region-specific changes in the brainstem involving energy use and stress-response signaling. The brainstem helps regulate automatic body functions, so mapping changes there may eventually connect to questions families have about breathing, heart rhythm, and other autonomic issues, but this study did not test treatments or directly link the findings to patient outcomes. It mainly provides a starting map of biological changes that could be explored in future studies. [8]

For families, the genetics study most directly adds information that may matter now because it shows how often SCN1A is found in people diagnosed with Dravet syndrome, and it highlights that Dravet-like conditions can be caused by several other genes. It also provides a clear example that medication effects can differ by gene, including reported seizure worsening with oxcarbazepine in some GABA receptor gene variants and a favorable response in a SCN2A gain-of-function case. [6]

The MRI and mouse biology studies mainly add understanding for the future rather than changing anything immediately. The MRI report suggests that structural differences on brain scans can show up in SCN-related epilepsies and may differ across genes, but it does not show how well these findings predict day-to-day outcomes. [7] The mouse study points to specific brainstem pathways that could be explored as future targets, but animal findings do not reliably predict what will help patients. [8]

This month included one preclinical study that moved beyond a single lab model by testing the same experimental compound in zebrafish, mice, and patient-derived nerve cells. The overall pattern was consistent across these models: the lead compound 20e reduced seizure-like activity and helped normalize abnormal brain-cell signaling in SCN1A-related disease models. This kind of step-by-step testing helps researchers judge whether a compound is promising enough to consider for future human studies, but it does not show whether it will work or be safe in people with Dravet syndrome. [9]

In the study, compound 20e reduced seizure-like movements in a zebrafish model and reduced seizure severity while delaying seizure onset in SCN1A haploinsufficient mice. In patient-derived iPSC neurons (lab-grown nerve cells made from patient samples), it reduced abnormal spike and burst activity, which researchers used as a sign of calmer, more typical network behavior. The researchers reported signals that the compound may work through serotonin-related pathways and also described favorable early safety and oral drug-like properties in their testing. [9]

For patients and caregivers, the value of this study is mainly that it identifies a new possible direction for future medicine development, not that it offers an option available now. Because the findings come from animal models and lab-grown nerve cells, it is still unknown whether the compound would be effective or safe in people, or what side effects might occur. What became clearer this month is that researchers can now point to a specific new chemical series and a possible mechanism to study further in SCN1A-related Dravet syndrome. [9]